Organisation paid for research Program year 2025 Source: CMS Open Payments

Toi Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$954,897

288 payments

Through program year 2025, Toi Clinical Research is reported as receiving $954,897 in research payments, across 288 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $129,743 63
2024 Research $218,043 126
2023 Research $599,735 97
2022 Research $7,376 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. Aadi Bioscience, Inc. $317,027 6 payments
  2. G1 Therapeutics, Inc. $87,250 10 payments
  3. Ge Healthcare $86,337 28 payments
  4. Janssen Research & Development, LLC $72,943 15 payments
  5. Acrotech Biopharma LLC $57,669 17 payments
  6. Mirati Therapeutics, Inc. $46,863 20 payments
  7. Astellas Pharma Global Development $42,635 13 payments
  8. Regeneron Pharmaceuticals, Inc. $37,948 20 payments
  9. Daiichi Sankyo Inc. $26,724 78 payments
  10. Incyte Corporation $23,913 9 payments
Studies the money was for Research payments · program years 2022–2025
  1. Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) $283,735 1 payment
  2. G1t28-207 $87,250 10 payments
  3. Impact of Cerianna PET/CT on Treatment Decisions in Metastatic Breast Cancer Patients $86,337 28 payments
  4. A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma $42,635 13 payments
  5. Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia $40,173 2 payments
  6. Spi-Fol-102 $39,094 11 payments
  7. A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. $33,292 5 payments
  8. A Phase 1/2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% $31,321 10 payments
  9. A Phase 3 Study Comparing Daratumumab VELCADE bortezomib Lenalidomide and Dexamethasone DVRd with VELCADE Lenalidomide and Dexamethasone VRd in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy $29,270 12 payments
  10. A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio $28,200 4 payments
What the money was spent on Research payments · program years 2022–2025
  1. Non-patient care $36,400 15 payments
  2. Patient care $10,463 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record